The Tylenol autism and ADHD Lawsuits are class action lawsuits filed in the United States District Court for the Southern District of New York. The Tylenol lawsuits allege that Johnson & Johnson, the makers of Tylenol, failed to warn consumers about potential risks associated with taking acetaminophen during pregnancy and its possible link to autism spectrum disorder (ASD) and other developmental disorders in children, including severe ADHD.

Attorneys Marin, Barrett, and Murphy on the Courthouse steps working on a tylenol autism adhd lawsuits
Contact Us for a Free Tylenol Autism ADHD Case Evaluation

The Tylenol autism and ADHD Lawsuits are class action lawsuits filed in the United States District Court for the Southern District of New York. The Tylenol lawsuits allege that Johnson & Johnson, the makers of Tylenol, failed to warn consumers about potential risks associated with taking acetaminophen during pregnancy and its possible link to autism spectrum disorder (ASD) and other developmental disorders in children, including severe ADHD.

Who Is Pursuing a Tylenol Autism Lawsuit?

The Marin, Barrett, and Murphy Law Firm is currently pursuing Tylenol autism lawsuits on behalf of parents or guardians of children with autism (ASD) or Attention-deficit/hyperactivity disorder (ADHD) after prenatal exposure to Tylenol or a generic acetaminophen product. Contact us today (888) 348-2735 for a free, no obligation claim evaluation or complete our contact form to receive a call or email at your convenience and around your schedule. While there is no definitive scientific evidence linking acetaminophen use during pregnancy to an increased risk of autism spectrum disorder, recent studies have suggested a possible association between prenatal exposure to certain medications like acetaminophen and an increased risk of ASD and ADHD. We can help you determine if you have a viable Tylenol claim.

The growing number of mass tort Tylenol autism lawsuits has recently prompted the consolidation of new multi-district litigation of all Tylenol autism lawsuits from around the country before Judge Denise L. Cote in the United States District Court for the Southern District of New York. Judge Cote’s recent ruling in the Tylenol autism litigation will allow this litigation to move forward in the multi-district litigation. Call today to speak with our Tylenol autism lawyers for a free, no obligation legal consultation or complete our contact form to find a lawyer for Tylenol autism lawsuit.  Please review the our webpage for new information about the Tylenol autism lawsuit and regular updates on the Tylenol autism lawsuit.

Attorney Matthew Marin specializing in Acetaminophen pregnancy lawsuits at Marin Barrett Law Firm

Join the litigation by filing a Tylenol Autism and ADHD Lawsuit Today

Our Tylenol injury attorneys are helping parents take legal action against Tylenol by pursuing mass tort lawsuits for children who were diagnosed with autism (ASD) or attention deficit / hyperactivity disorder (ADHD) after being exposed to increased levels of acetaminophen (Tylenol) in the womb. Newly released scientific evidence over the last two years has shown a correlation between increased levels of acetaminophen (the generic name for the over-the-counter pain reliever Tylenol) in cord blood samples and umbilical cord blood from newborns and the subsequent development of ASD or ADHD. The newborns with elevated acetaminophen levels detected in their cord blood were roughly three times more likely to be diagnosed with ADHD or autism spectrum disorder (ASD) later in childhood compared to children with the lowest levels of acetaminophen in their cord blood.

Researchers at the Johns Hopkins Bloomberg School of Public Health analyzed data from pairs of mothers and children in the Boston Birth Cohort, a 20-year study of early life factors influencing pregnancy and child development. In this cohort study of 996 mother-infant dyads from the Boston Birth Cohort, cord plasma biomarkers of fetal exposure to acetaminophen were associated with significantly increased risk of childhood attention-deficit hyperactivity disorder and autism spectrum disorder. These findings suggest in utero exposure to acetaminophen is associated with increased risk of attention-deficit/hyperactivity disorder and autism spectrum disorder in children and warrant additional investigations.

While the drug makers and Johnson & Johnson continue to dispute the legal basis of the cases that are being filed against them, the Marin, Barrett, and Murphy Law Firm stands ready to join the fray by providing legal assistance for Tylenol and autism cases and suing to obtain justice in the court of law for your child.  If you think your child’s autism diagnosis or attention deficit hyperactivity diagnosis may be due to exposure to the over-the-counter drug acetaminophen or Tylenol during pregnancy, take legal action today and contact the Tylenol autism injury attorneys at Marin, Barrett, and Murphy for a free case evaluation and join the litigation. Our Tylenol autism lawyers are available 24/7 at (888) 348-2735 to take your call and stand ready to fight for you and your child. We believe that the manufacturers and retailers of Tylenol and acetaminophen should have warned the public of the dangers of its product and the risks of autism when used by pregnant women. If they had been properly warned of the risk of autism if taking acetaminophen during pregnancy, it may have allowed them to take precautionary actions.

Tylenol Acetaminophen Autism ADHD Lawsuit

Is the Tylenol and Acetaminophen Autism ADHD Lawsuit Real?

Yes, parents whose children have experienced the development of autism or severe ADHD are pursuing legal mass tort claims by filing Tylenol lawsuits alleging that the use of Tylenol or acetaminophen products during their pregnancy caused their child to develop autism spectrum disorder, severe ADHD, neurodevelopmental disorders, neurological disorders, developmental disorders, defiant disorder, and other mental health effects. The Tylenol manufacturers are being sued for negligently failing to warn about the likelihood of autism after usage during pregnancy. The lawsuits seek financial compensation to parents on behalf of ADHD and autistic children for the permanent disability caused by prenatal exposure to different brands of acetaminophen during important periods of fetal brain development.

The focus of these lawsuits has been on the use of the over-the-counter medication acetaminophen, commonly known as Tylenol (the brand name), during pregnancy and it’s impact on fetal development. Brand name acetaminophen is known as Tylenol and is manufactured by Johnson & Johnson. Johnson & Johnson owns the rights to the active ingredient list through an acquisition of the original company in 1958. Recently, many retailers such as Walmart and CVS have developed generic acetaminophen products of their own through other manufacturers. Other generic retailers of acetaminophen being sued in this litigation include Safeway, Walmart, Target, CVS, Walgreens, Costco, Rite Aid, Sam’s Club, Dollar Tree, and Kroger.

Other acetaminophen drug manufacturers who have been included in the acetaminophen dangerous drug lawsuits include LNK, International, Inc., Perrigo Company plc, Ohm Laboratories, Inc., Aurobindo Pharma Ltd., Humanwell PuraCap Pharmaceuticals (Wuhan) Co., Ltd., Elysium Pharmaceutical Ltd., Medgel Private Ltd., Aurohealth LLC, AptaPharma Inc., APL Healthcare, Ltd., Hi-Tech Nutraceuticals, LLC, and Johnson & Johnson Consumer Inc.

Tylenol and Autism ADHD Lawsuits Updates

August 17th, 2023 Update: As of early August there were over 200 Tylenol Autism and ADHD claims filed into the Tylenol Class Action MDL.  Undoubtedly, thousands of more claims are being readied to be filed pending the outcome of important hearings and events this fall.  Attorneys and clients are awaiting a filing by the FDA on September 15th.  The filing, known as a ‘statement of interest’, will indicate the FDA’s views on the labeling for over-the-counter acetaminophen products and will potentially factor into the Court’s rulings and the Defendant’s willingness or unwillingness to settle claims.

Additionally, both plaintiff and defendant Daubert filings are due to the Court on September 19th.  With these filings, the Court will be able to schedule and hear Daubert arguments regarding the sufficiency of the Plaintiff’s medical expert testimony and supporting scientific research and documentation.  If the Plaintiff’s are successful and present sufficient evidence to the Court linking Tylenol and/or acetaminophen use to either Autism or ADHD, the claims will then proceed to a bellwether trial process where individual cases will be selected for trial.  We anticipate hundreds, if not thousands, of additional claims will be filed into the MDL if the plaintiffs are successsful in the Daubert hearings.

June 19, 2023 Update: In recent weeks, there have been developments in the Tylenol lawsuit concerning the potential accountability of retailers like CVS, Target, and Walmart for their failure to warn customers about the potential risks of using their own store-branded acetaminophen products during pregnancy; specifically the potential for an increased risk of autism or ADHD in children.

Despite the arguments put forth by Target and Walmart, arguing that compliance with federal laws shields them from liability under state law, MDL Judge Denise L. Cote of the U.S. District Court for the Southern District of New York ruled that the lawsuit filed by individual claimants is subject to each particular Plaintiff’s state law. In one case, Judge Cote determined that a 1993 ruling by the California high court does not prohibit a lawsuit from moving forward. On the other hand, other claims made by Plaintiffs in Texas fall under Texas law and Judge Cote ruled that those claims should be dismissed.

In conclusion, it looks as if we will also see a large number of lawsuits involving retailers such as CVS, Target, and Walmart in addition to the brand Tylenol as the cases move forward, depending on each individual Plaintiff’s particular state laws.

May 24, 2023 Update: In response to the refusal of a federal judge to dismiss lawsuits linking Tylenol usage during pregnancy to increased risk of autism or ADHD in children, Johnson & Johnson (J&J) has filed for an interlocutory appeal. If successful, this would allow the question of whether federal law should preempt failure to provide sufficient warnings to be addressed by a federal appeals court. Currently, these consolidated lawsuits involve over 100 families claiming J&J violated state laws by not adequately warning about potential risks associated with Tylenol’s active ingredient, acetaminophen.

Judge Denise Cote, who oversees the consolidated lawsuits, has previously rejected J&J’s claim that FDA regulations exempted them from the need to add a risk warning to their acetaminophen products. The future direction of the case, including potential scheduling of initial bellwether trials in the Multidistrict Litigation (MDL), depends on the outcome of J&J’s appeal. If the appeal is rejected or if the preemption argument fails to hold up in review, we may see the first of these trials scheduled.

April 21, 2023 Update: U.S. District Judge Denise Cote has denied Johnson & Johnson’s motion to dismiss 72 lawsuits in the ongoing Tylenol Autism ADHD litigation. The lawsuits assert that using Tylenol during pregnancy escalates the chances of children developing autism or ADHD. Despite J&J’s assertion that FDA regulations preempted claims that it didn’t warn of Tylenol’s prenatal risks, Judge Cote ruled that J&J could have included a truthful warning regarding in utero exposure to acetaminophen on Tylenol labels without contravening federal law.

This latest ruling applies to 72 cases within the multidistrict litigation, adding a renewed sense of optimism for the plaintiffs. The judge has requested the U.S. government, including the FDA, to review the plaintiffs’ proposed warning label change. The upcoming months will play a crucial role in determining the future of this litigation, particularly as the courts await further scientific studies on the potential link between prenatal acetaminophen use and autism spectrum disorder or attention deficit hyperactivity disorder.

November 15, 2022 Update: In a major early victory for the Plaintiffs in the Tylenol Autism ADHD lawsuits, United States District Court Judge Denise Cote denied Walmart’s motion to dismiss claims against it’s generic version of Tylenol called Equate.  Judge Cote determined that federal law, including FDA regulation of labeling of Tylenol, did not prevent or preement a State law Tylenol lawsuit alleging the warning labels on Tylenol and generic acetaminophen products were insufficient to warn pregnant women of the risk of autism and ADHD. The Federal Court ruling brings renewed momentum to the Tylenol Autism ADHD lawsuit and a more positive outlook on the future of this litigation.

November 14, 2022 Update: A status conference on the Tylenol class action MDL will be held on Thursday, November 17, 2022. From what we understand the judge overseeing the case, Judge Denise Cote, will be expected to name her selections for the Tylenol autism lawyers plaintiffs leadership committee and to outline the pretrial proceedings by establishing a discovery plan and tentatively scheduling the trial dates for the product liability claims bellwether trials.

November 13, 2022 Update: Walmart filed a motion to dismiss the Equate (Walmart’s brand Acetaminophen) lawsuit that two plaintiffs have filed out of Arkansas against them on the basis of federal preemption. The class action against alleges that Walmart under state law failed to warn about the risk of taking its Equate-brand Acetaminophen during pregnancy. In the motion to dismiss, Walmart argued that the warning labels on these products are mandated by the FDA under federal law, and that they couldn’t change the labels. The Plaintiffs have responded that FDA regulations never prevented them from making changes to the warning labels to express the risk of the pain reliever to those who are pregnant.  

November 8, 2022 Update: While Johnson & Johnson has not been named yet in lawsuit, it does look like several retailers will be.  A Tylenol ADHD and autism class action lawsuit was approved by a judge this week to help guide the structure of the defense counsel committee.  A “Retailer Liaison Committee” (RLC) will also be formed within the structure that will serve as a liaison between the plaintiffs and the lawyers defending the selected retailers. 

October 5, 2022 Update: The Judicial Panel on Multidistrict Litigation has certified a class action lawsuit in New York that will house all Tylenol lawsuits filed in any federal court in the U.S. The Tylenol multidistrict litigation was established after the JPML found there were a large number of lawsuits filed against the manufacturer of Tylenol alleging a link between Tylenol and autism and ADHD. The purpose of the creation of the Tylenol MDL is to streamline the pretrial proceedings in the litigation process and to avoid duplicative or conflicting rulings in different courts.

The creation of an MDL can be beneficial for both plaintiffs and defendants, as it allows for more efficient and cost-effective resolution of the cases. For plaintiffs, an MDL can provide a more convenient forum for their cases because the cases will all be heard by a single judge and allow for coordinated discovery with other similar cases. For defendants, an MDL can help to minimize the costs and risks associated with litigating a large number of similar cases in multiple courts across the country.

Projected Tylenol Autism ADHD Settlement Amounts

At this point in time, it is nearly impossible to provide a specific projection for Tylenol autism or ADHD settlement amounts as these lawsuits are still in the very early stages of the discovery process. Any future potential settlement amounts for the Tylenol autism class action lawsuits will depend on a number of factors, including the specific details of each case, the strength of the evidence for each plaintiff, and the negotiating skills and experience of the lawyers involved.

Settlement amounts in product liability cases, including Tylenol autism and ADHD cases, can vary widely. Some Tylenol lawsuit settlements may be for a few thousand dollars, while others can be for millions of dollars. The amount of a settlement will depend on a number of factors including the severity of the injury, the impact on the individual’s quality of life, and the costs associated with past and future medical treatment.

It’s important to note that settlement negotiations in Tylenol autism and ADHD cases may be confidential and the terms of the settlement are not typically made public. As a result, it’s difficult to predict what a settlement amount might be in a specific case. If you are considering filing a Tylenol autism or ADHD lawsuit, it’s important to speak with a team of personal injury attorneys who have experience handling these types of cases involving unborn children and taking on the drug makers and pharmaceutical companies. An attorney can help you understand your legal options, the settlement process and assist you in negotiating a settlement that is fair and just and work to maximize your potential compensation you receive for your legal claims. Our team at Marin, Barrett, and Murphy has experience in this type of litigation and can help guide you through the process to get the Tylenol lawsuit compensation you deserve.